

Weight gain in children and adolescents on dolutegravir vs standard of care in the **ODYSSEY** trial



A-IAS2021-01311

Rosie Mngqbisa, Ngundu Osee Behuhuma, Hajira Kataike, Godfrey Musoro, Annet Nandudu, Pauline Amuge, Shafic Makumbi, Siva Danaviah, Shabinah Ali, Ben Wynne, Yoann Riault, Steve Welch, Tim R Cressey, Avy Violari, Alexandra Compagnucci, James Hakim, Pablo Rojo, Carlo Giaquinto, Diana M Gibb, Deborah Ford, the ODYSSEY trial team 1 MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, United Kingdom; 2 Joint Clinical Research Centre (JCRC), Kampala, Uganda; 3 University of Zimbabwe, Harare, Zimbabwe; 4 Perinatal HIV Research Unit, University of the Witwarsrand, Johannesburg, South Africa; 5 Baylor College of Medicine, Uganda; 6 Joint Clinical Research Centre (JCRC), Mbarara, Uganda; 7 Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda; 8 Prapokklao Hospital, Chanthaburi Province, Thailand; 9 Family Center for Research with Ubuntu, Department of

Paediatrics & Child Health, Stellenbosch University, Tygerberg, South Africa; 10 HIVNAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand; 11 Enhancing Care Foundation: King Edward VIII Hospital; 12Africa Health Research Institute (AHRI), Kwazulu-Natal, South Africa; 13 INSERM/ANRS SC10-US19,

Essais thérapeutiques et maladies Infectieuses, Villejuif, France; 14 Department of Paediatrics, Heartlands Hospitals Birmingham, UK; 15 PHPT/IRD Research Unit, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand 16 Pediatric Infectious Diseases Unit, Hospital 12 de Octubre, Madrid, Spain; 17 University of Padova, Department of Women and Child Health, Padova, Italy

Anna Turkova, Cissy Kityo, Hilda A Mujuru, Ebrahim Variava, Adeodata Kekitiinwa, Abbas Lugemwa, Linda Barlow-Mosha, Chaiwat Ngampiyaskul, Peter Zuidewind, Thanyawee Puthanakit,

correspondence to a.turkova@ucl.ac.uk


Background

- Dolutegravir is associated with excessive weight gain in adults.
- ADVANCE trial reported 10kg weight gain on DTG+TAF/FTC and 6kg on DTG+TDF/FTC over 144 weeks.[1]
- There are limited and conflicting data on DTGassociated weight gain in observational studies in children.
- A study in the UK CHIPS cohort (n=300) showed no difference in change of BMI-for-age at 12 months after switch to DTG vs PI-based ART in virologically suppressed children.[2]
- A retrospective study in Eswatini (n=460)showed that switch to DTG in virologically suppressed adolescents was associated with an increase in the rate of BMI gain. [3]
 - A small study in the US adolescents (n=51) has also shown a greater rate of BMI and BMI-for-age increase following switch to INSTI [4]
 - We present the first randomised data in children and adolescents.

Methods

- ODYSSEY is a randomised multi-country trial evaluating dolutegravir + 2NRTIs (DTG) versus standard-of-care (SOC) in children starting firstline or second-line ART
- The main trial enrolled children ≥14kg between September 2016 and June 2018
- We compared weight, height, BMI and BMI-for-age Z-scores (BAZ) between treatment arms using normal regression models adjusting for first-/second-line, randomisation stratification factors and baseline measurements
- The difference in treatment effect on BAZ in the DTG and SOC arms was assessed by first- and second treatment lines, sex, age and NRTI backbone (non-TDF vs TDF)
- Proportions becoming newly overweight (BAZ>1-≤2) or newly obese (BAZ>2) are described

ODYSSEY trial schema



Results

- 707 children were randomised (sub Saharan Africa 88%, Thailand 9%, Europe 4%)
- 311 started first-line (92% efavirenz-based in SOC); 396 second-line (72% lopinavir/ritonavir, 25% atazanavir/ritonavir in SOC)
- 65% initiated ABC+3TC, 23% TDF+XTC, 11% ZDV+3TC
- At baseline, median age was 12.2 years (IQR 9.1, 14.9; range 2.9-18.0)
- 49% were female
- Median follow-up 142 weeks (IQR 124, 159)

Population at baseline (n=707)

Weight, Height and BMI at baseline

	Median	IQR	Range
Weight, kg	31	(24, 43)	[14 to 85]
Height, cm	138	(125, 153)	[89 to 182]
BMI, kg/m ²	16.3	(14.9, 18.5)	[9.8, 34.5]
BMI-for-age, Z-score*	-0.6	(-1.4, 0.0)	[-7.8, 2.8]

*using UK WHO Term Reference 2009


At baseline

- 11% had severe thinness/thinness (BMI-for-age <-2 SD)
- were overweight • 1% obese

(BMI-for-age >1SD to ≤ 2 SD) (BMI-for-age >2SD)


Change in weight and height


Weight: change from baseline **DTG-SOC** (95%CI 0.3,1.7) p=0.00448 60 72 84 96



- Small additional gains from baseline in weight and height in DTG vs. SOC
- At 96 weeks mean additional gain in DTG vs SOC in weight was 1kg, and in height 0.8cm
- The differences occurred early and stabilised

Change in body mass index (BMI) and BMI-for-age





- Small additional gains from baseline in BMI and BMI-for-age in DTG vs. SOC
- Over 96 weeks mean additional gain in BMI in DTG vs SOC was 0.3 kg/m², and in BAZ 0.12 SD


The gap between arms did not increase with time


Results

Change in BMI-for-age: by sex

BMI-for-age: males (N=362)









• Treatment effects did not differ significantly between boys and girls (heterogeneity p=0.37)


Change in BMI-for-age: by baseline age group

BMI-for-age: <12 years (N=343)

→ DTG ⊢ SOC









• There was no difference in treatment effects by age group (heterogeneity p=0.78)

Change in BMI-for-age: by TDF at baseline

BMI-for-age: no TDF (N=543) BMI-for-age: TDF (N= 164)





· Treatment effects did not differ significantly between children not on TDF and those on TDF (heterogeneity p=0.65)

New overweight and obesity

- Overall, 25 (4%) were newly overweight or obese at 96 weeks: 14 (4%) in the DTG arm & 11 (3%) in SOC (p=0.55)
- Characteristics of those newly overweight or obese: Median age at enrolment: 13.0 years (IQR 10.3, 15.4)
- 15/311 (5%) on first-line vs 10/396 (3%) on second-line ART
- 15/345 (4%) females vs 10/362 (3%) males
- 10/167 (6%) on TDF vs 15/540 (3%) not on TDF

Conclusions

- Children grew better after starting DTG compared to non-DTG ART
- Differences between arms in weight, height and BMI were small and stabilized
- Differences between arms were similar by: first- or second-line, sex, age and NRTI backbone (non-TDF / TDF)
- Few became newly overweight or obese in either arm
- DTG-based ART was not associated with excessive weight gain in children and adolescents

References

- 1. Hindley. CROI 2021. Abs 117 2. Crichton et al. HIV Pediatrics 2019
- 4. Dirajlal-Fargo et al. CROI 2020

3. Thivalapill et al. CID 2020

Clinical

Trials MRC













CeSHHAR









Essais Thérapeutiques





